Pseudomyxoma Peritonei Clinical Trials

7 recruitingLast updated: May 4, 2026

Pseudomyxoma Peritonei Trials at a Glance

8 actively recruiting trials for pseudomyxoma peritonei are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Basingstoke, Beijing, and Leuven. Lead sponsors running pseudomyxoma peritonei studies include Oslo University Hospital, Institut du Cancer de Montpellier - Val d'Aurelle, and Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

Browse pseudomyxoma peritonei trials by phase

Treatments under study

About Pseudomyxoma Peritonei Clinical Trials

Looking for clinical trials for Pseudomyxoma Peritonei? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pseudomyxoma Peritonei trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pseudomyxoma Peritonei clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 3

Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)

Pseudomyxoma Peritonei
University of Southampton176 enrolled1 locationNCT06513065
Recruiting
Not Applicable

Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis

Peritoneal CarcinomatosisPseudomyxoma PeritoneiMesothelioma Peritoneum
Institut du Cancer de Montpellier - Val d'Aurelle60 enrolled1 locationNCT04024917
Recruiting
Early Phase 1

Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei

Pseudomyxoma Peritonei
Oslo University Hospital10 enrolled1 locationNCT07341360
Recruiting
Not Applicable

One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei

Pseudomyxoma Peritonei
Beijing Tsinghua Chang Gung Hospital132 enrolled1 locationNCT07328737
Recruiting
Phase 2

Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients

Pseudomyxoma Peritonei
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano31 enrolled1 locationNCT06800391
Recruiting

Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed

Peritoneal CarcinomatosisPeritoneal MesotheliomaPseudomyxoma Peritonei
Universitaire Ziekenhuizen KU Leuven125 enrolled1 locationNCT01617382
Recruiting

Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies

Ovarian CarcinomaColorectal CarcinomaMesothelioma+1 more
Oslo University Hospital300 enrolled1 locationNCT02073500
Recruiting
Phase 2

Injection of Bromelain and Acetylcysteine in combination into recurrent mucinous tumour or pseudomyxoma peritonei: a phase I/II study

recurrent pseudomyxoma peritoneilow grade appendix tumour
Professor David Morris60 enrolled2 locationsACTRN12617001612303